Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100

Trial Profile

Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Heart transplant rejection
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 14 Oct 2015 According to ClinicalTrials.gov, this study has been terminated because of slow enrolment.
    • 14 Oct 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 11 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top